Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of dupilumab in allergic fungal rhinosinusitis
MOH_2021-02-17_009397Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic fungal rhinosinusitis (AFRS) comparing Dupixent with Matching placebo (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on MOH_2021-02-17_009397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-17_009397.